Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Autoimmune Diseases

• Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting
• CAR-T in Subjects With Relapsed/Refractory Autoimmune Disease
• An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis
• Inectolizumab With Steroid Optimization in Newly Treated NMOSD
• A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
• Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
• A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
• A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
• Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
• A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
• CAR-T Therapy for Refractory Autoimmune Diseases
• CAR-T Cells Therapy for Patients With Autoimmune Diseases
• A Study of CAR-T Cells in Subjects With Autoimmune Diseases
• Study to Access the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
• Atacicept in Multiple Glomerular Diseases
• Study of BHV-1300 in Graves' Disease
• Effect of Transcutaneous Electrical Acupoint Stimulation on Dysmenorrhea Among Autoimmune Disease Women
• Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia
• Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
• A Continuation Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
• Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder
• The Therapeutic Effect of Curcumin in Nanogels Compared to 0.1% FAO in the Management of Oral Lichen Planus
• JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs)
• Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
• Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis
• A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.
• Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants
• A Study of CAR-T Cells in Subjects with Autoimmune Diseases
• A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
• CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)
• A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases
• A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Tiral in Healthy Male Volunteers
• Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis
• A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
• US Zamto-cel Autoimmune Diseases
• Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
• PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
• A Research Study Looking at the Safety of Single Doses of ZP9830 and How it Works in the Body of Healthy Participants
• CD19 CAR-T in the Treatment of Relapsed/Refractory Autoimmune Diseases
• IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
• A Dose Escalating Study of HC002 in Healthy Adult Volunteers
• A Study of CAR-T Cells Targeting Autoimmune Diseases
• The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD
• A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
• Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases
• Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
• Complement C5 mAb in the Treatment of Anti-GBM Disease
• An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases
• Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease
• Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease
• Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
• Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
• A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
• KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
• KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
• A Phase 1 Study of ADI-001 in Autoimmune Disease
• KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
• A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants
• A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases
• A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
• A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
• The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
• A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
• F01 in the Treatment of Autoimmune Diseases
• A SHR0302 BA Study on Healthy Subjects
• CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
• An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus
• Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers
• First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug;LPX-TI641
• Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
• Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects
• An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Autoimmune Disorders
• Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
• Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement
• Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes
• A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease
• Immunomodulatory Therapy in Women With Autoimmune Premature Ovarian Insufficiency
• A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis
• A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)
• A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses
• To Evaluate the Safety of Treating Rheumatologic and Metabolic Patients With Molecular Hydrogen Supplement.
• To Evaluate the Safety of Treating Autoimmune Diseases With Molecular Hydrogen Supplement
• Safety and Efficacy of Intrathecal Rituximab in Patients With Multiple Sclerosis
• Effect of One-week vs Two-week Discontinuation of Methotrexate on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial
• COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
• Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo
• A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects
• Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity
• A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy
• Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Idiopathic Inflammatory Diseases of the Nervous System
• Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
• Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects
• Safety and Tolerability of GX-P1 in Healthy Male Volunteers
• Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
• A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis
• Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants
• Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus
• Withdraw Drug in Stable IgG4-Related Disease
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Health Subject
• Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS
• Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects
• Human Absorption, Distribution and Metabolism Study (hAME) [14C]-KD025
• Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" Trial
• Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)
• Leflunomide Treatment for IgG4-RD
• Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
• Personalized Therapies in Inflammatory Complex Disease
• A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772
• Phase I Study of GSK2982772 in Japanese Healthy Male Participants
• Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis
• Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers
• Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
• Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis
• A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects
• A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)
• Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis
• Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients
• Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
• Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
• A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders
• SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study
• Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan
• Apremilast Pregnancy Exposure Registry
• Pilot Study of a New Device (Buzzy®) for Procedural Pain Relief During Needle-Related Procedures in Paediatric Patients
• Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
• Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease
• Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
• A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis
• Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
• Diabetes Islet Preservation Immune Treatment
• Study of Treatment Response on IgG4 Related Disease (IgG4RD)
• Transcriptome Analysis of the Peripheral Blood in CIDP
• Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers
• Phase 1 Study Accessing the Safety and Tolerability of CBP-307
• Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection
• Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP)
• A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants
• Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy
• Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)
• Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
• Concentration/Meditation Limits Inflammation
• Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
• Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis
• 18F-FDG PET/CT for IgG4-Related Disease
• Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome
• Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
• Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia.
• IVIG Treatment for Refractory Immune-Related Adult Epilepsy
• On Open-Label Study in Participants With Systemic Lupus Erythematosus
• A Single and Repeat Dose PK/PD Study to Characterise Biomarker Response in Healthy Subjects Treated With Azithromycin
• Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain
• A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
• Intravenous Immunoglobulin for PANDAS
• A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
• A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
• Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
• Diabetes Virus Detection Project, Intervention With GAD-alum
• Rituximab for Autoimmune Retinopathy
• Auto-immunity in Lupus Patients After Influenza Vaccine
• Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
• Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
• Phase 0 Microdose Study
• The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
• Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
• Whole Lung Lavage (WLL)/Inhaled Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (PAP)
• Calcitriol in the Treatment of Immunoglobulin A Nephropathy
• Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
• Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease
• Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells
• Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases
• A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
• Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
• Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
• Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate
• A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
• Lab Study of MQX-503 in Treatment of Raynaud's
• Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project
• Scleroderma: Cyclophosphamide or Transplantation
• Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
• Treatment of Multiple Sclerosis With Copaxone and Albuterol
• Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
• Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome
• Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
• Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)
• Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections